Advancing Treatment in Pediatric Multiple Sclerosis: The Promise of B-Cell-Targeting Therapies

Area of Science:

• Neuroimmunology
• Demyelinating Diseases

Background:

• Pediatric-onset multiple sclerosis (POMS) is a rare central nervous system demyelinating disease.
• POMS exhibits a more inflammatory disease course and higher relapse rates than adult-onset MS (AOMS).
• Early intervention with high-efficacy disease-modifying therapies (DMTs) is crucial to prevent neurological damage in POMS.

Purpose of the Study:

• To review the role of B-cells in POMS pathophysiology.
• To evaluate the therapeutic potential of anti-CD20 monoclonal antibodies for POMS.
• To discuss emerging B-cell-directed therapies and future treatment strategies for POMS.

Main Methods:

• Literature review of current knowledge on POMS.
• Analysis of B-cell involvement in POMS pathogenesis.
• Evaluation of anti-CD20 therapies and other novel B-cell-targeting agents.

Main Results:

• B-cells play a significant role in the immunopathogenesis of POMS.
• Anti-CD20 monoclonal antibodies demonstrate therapeutic potential for POMS, similar to their efficacy in adult MS.
• Several novel B-cell-directed therapies are under investigation for POMS.

Conclusions:

• B-cell-targeting therapies, particularly anti-CD20 agents, represent a promising treatment avenue for POMS.
• Early initiation of effective DMTs is essential for managing POMS.
• Future research should focus on novel B-cell-directed approaches like anti-CD19 therapies, BTK inhibitors, and BAFF-targeting agents for POMS.